ArticleESMO gastrointestinal oncology2026
Nivolumab plus ipilimumab and cobimetinib in previously treated microsatellite-stable/DNA mismatch repair-proficient metastatic colorectal cancer: the phase II CheckMate 142 trial.
M J Overman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.